Nuvalent, Inc. (NUVL): Price and Financial Metrics
GET POWR RATINGS... FREE!
NUVL Stock Price Chart Interactive Chart >
NUVL Price/Volume Stats
|Current price||$32.46||52-week high||$40.43|
|Prev. close||$33.08||52-week low||$7.09|
|Day high||$33.40||Avg. volume||165,406|
|50-day MA||$30.93||Dividend yield||N/A|
|200-day MA||$19.71||Market Cap||1.83B|
Nuvalent, Inc. (NUVL) Company Bio
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Most Popular Stories View All
NUVL Latest News Stream
|Loading, please wait...|
NUVL Latest Social Stream
View Full NUVL Social Stream
Latest NUVL News From Around the Web
Below are the latest news stories about NUVALENT INC that investors may wish to consider to help them evaluate NUVL as an investment opportunity.
Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 7:30 a.m. PT in San Francisco.
Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Nuvalent, Inc. has attracted market interest, while headwinds have put the entire biotech sector under upward pressure. Read why NUVL is overvalued.
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1. NVL-520 is currently being studied in the ongoing ARROS-1 Phase 1/2 clinical tri
In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]
NUVL Price Returns